马来酸曲美布汀联合舒肝颗粒治疗功能性消化不良的临床疗效及安全性评价  

Clinical efficacy and safety of trimebutine combined with Shugan granule in the treatment of functional dyspepsia

作　　者：于惠玲[1] 鲁素彩[1] 孟杰[1] 王阳阳[1] 常颖[1] 门路 高蕊[1] 丁静[1] 

机构地区：[1]河北大学附属医院消化科,河北保定071000

出　　处：《中国临床药理学杂志》2016年第6期499-501,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的评价马来酸曲美布汀联合舒肝颗粒治疗功能性消化不良的临床疗效及安全性。方法将84例功能性消化不良患者随机分为对照组42例和试验组42例。对照组口服马来酸曲美布汀0.2 g,tid;试验组在对照组的基础上,口服舒肝颗粒3 g,bid。2组患者均治疗4周。比较2组患者的临床症状积分、焦虑自评量表(SAS)和抑郁自评量表(SDS)评分,以及不良反应发生率。结果治疗后,试验组的临床症状积分以及SAS评分、SDS评分均显著低于对照组(P均<0.05)。2组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论马来酸曲美布汀联合舒肝颗粒治疗功能性消化不良可改善患者的临床症状及焦虑抑郁状态,且不增加不良反应发生率。Objective To evaluate the clinical efficacy and safety of trimebutine combined with Shugan granule in the treatment of functional dyspepsia. Methods A total of 84 patients with functional dyspepsia were randomly divided into control group（ n = 42） and treatment group（ n = 42）. Control group was treated with trimebutine 0. 2 g,tid for 4weeks. Treatment group was treated with trimebutine 0. 2 g,tid and Shugan granule 3 g,bid for 4 weeks. The clinical symptom scores,self-rating anxiety scale（ SAS） and self-rating depression scale（ SDS）scores,and incidence of adverse drug reactions were compared between the two groups. Results After treatment,the clinical symptom scores,SAS and SDS scores in treatment group were significantly lower than those in control group（ all P〈0. 05）. The incidence of adverse drug reactions in two groups has no significant difference（ P〈0. 05）. Conclusion The combined therapy of trimebutine and Shugan granule can significantly improve the clinical symptoms and the states of anxiety and depression without increasing of the incidence of adverse drug reactions.

关 键 词：马来酸曲美布汀 舒肝颗粒 功能性消化不良 临床疗效 安全性 

分 类 号：R57[医药卫生—消化系统]